Pre-made Apamistamab benchmark antibody ( Whole mAb Radiolabelled, anti-PTPRC therapeutic antibody, Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. ... It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-029-1mg	1mg	Inquiry
GMP-Bios-ab-029-10mg	10mg	Inquiry
GMP-Bios-ab-029-100mg	100mg	Inquiry
GMP-Bios-ab-029-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody
INN Name	Apamistamab
Target	PTPRC
Format	Whole mAb Radiolabelled
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center
Conditions Approved	na
Conditions Active	Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma
Conditions Discontinued	Hodgkin's disease;Non-Hodgkin's lymphoma
Development Tech	na